AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q3 FY21 results · Oct–Dec 2020
AstraZeneca Pharma India reported revenue from operations of ₹200.25 crore (down 10.5% from Q3 FY20) and net profit of ₹21.05 crore (down 21.2% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a standalone basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 200.25 | 223.86 | −10.5% | 209.48 | −4.4% |
| Other income | 2.93 | 3.46 | −15.4% | 4.71 | −37.9% |
| Total income | 203.18 | 227.32 | −10.6% | 214.19 | −5.1% |
| Profit before tax | 28.30 | 35.18 | −19.6% | 35.57 | −20.4% |
| Net profit for the period | 21.05 | 26.70 | −21.2% | 26.34 | −20.1% |
| EPS, basic (₹) | 8.42 | 10.68 | −21.2% | 10.54 | −20.1% |
| Net margin (%) | 10.5 | 11.9 | 12.6 |
Standalone
- Filed with BSE
- 09 Feb 2021, 13:23 IST
- Board meeting
- 08 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE